Key Points
- AdaptHealth insider Russell Schuster III sold 11,275 shares on June 1 at an average price of $10.06, totaling $113,426.50. After the sale, he still held 136,538 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
- The company’s latest earnings missed profit expectations, reporting EPS of -$0.12 versus the consensus estimate of $0.01. However, revenue came in above forecasts at $819.8 million, up 5.4% year over year.
- Wall Street sentiment remains cautiously positive, with analysts assigning AdaptHealth an average “Moderate Buy” rating and a mean price target of $14.29. Several firms recently raised their targets, including Baird, Truist, Canaccord Genuity, and RBC.
AdaptHealth Corp. (NASDAQ:AHCO - Get Free Report) insider Russell Schuster III sold 11,275 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $10.06, for a total value of $113,426.50. Following the completion of the sale, the insider directly owned 136,538 shares in the company, valued at approximately $1,373,572.28. This represents a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AdaptHealth Trading Up 0.8%
NASDAQ AHCO opened at $9.73 on Thursday. AdaptHealth Corp. has a 12 month low of $8.06 and a 12 month high of $13.43. The stock has a market cap of $1.32 billion, a P/E ratio of -15.69, a P/E/G ratio of 0.55 and a beta of 1.47. The stock's fifty day moving average price is $11.56 and its 200-day moving average price is $10.55. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 1.21.
AdaptHealth (NASDAQ:AHCO - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.13). AdaptHealth had a positive return on equity of 2.76% and a negative net margin of 2.42%.The company had revenue of $819.80 million during the quarter, compared to analysts' expectations of $796.63 million. During the same period in the prior year, the company posted ($0.05) earnings per share. The company's revenue was up 5.4% on a year-over-year basis. As a group, equities analysts forecast that AdaptHealth Corp. will post 0.63 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on the company. Robert W. Baird set a $18.00 price objective on AdaptHealth in a research report on Wednesday, May 6th. Truist Financial increased their price objective on AdaptHealth from $13.00 to $14.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Canaccord Genuity Group increased their price objective on AdaptHealth from $14.00 to $16.00 and gave the company a "buy" rating in a research report on Wednesday, May 6th. Royal Bank Of Canada increased their price objective on AdaptHealth from $13.00 to $15.00 and gave the company an "outperform" rating in a research report on Monday, May 11th. Finally, Wall Street Zen raised AdaptHealth from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $14.29.
Get Our Latest Report on AdaptHealth
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of AHCO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in AdaptHealth by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company's stock worth $656,000 after purchasing an additional 2,564 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in AdaptHealth by 32.4% in the first quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company's stock worth $6,192,000 after purchasing an additional 139,828 shares during the last quarter. Woodline Partners LP purchased a new position in AdaptHealth in the first quarter worth about $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in AdaptHealth by 18.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company's stock worth $2,534,000 after purchasing an additional 35,879 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in AdaptHealth by 1.3% in the second quarter. JPMorgan Chase & Co. now owns 211,769 shares of the company's stock worth $1,997,000 after purchasing an additional 2,718 shares during the last quarter. 82.67% of the stock is owned by hedge funds and other institutional investors.
About AdaptHealth
(
Get Free Report)
AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.
The company's respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
